# Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients

> **NCT01997944** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Bio-Fortune Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** Human Serum ALbumin/interferon alpha2a
- **BIOLOGICAL:** Pegasys

## Key facts

- **NCT ID:** NCT01997944
- **Lead sponsor:** Beijing Bio-Fortune Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-09
- **Final completion:** 2014-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997944, "Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01997944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*